Severe asthma imposes a significant burden on patients, families and healthcare systems.
Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care …

Severe asthma often remains uncontrolled despite effective treatments and evidence-based
guidelines. A group of global experts in asthma and biologic medications from 9 countries …

Care pathways for the selection of a biologic in severe asthma | European Respiratory Society
Skip to main content Main menu Home Current issue ERJ Early View Past issues ERS …

Patients with uncontrolled severe persistent asthma have greater morbidity, greater use of
health care resources, and more impairment in health-related quality of life when compared …

Asthma is a heterogeneous chronic inflammatory disease of the airways that affects
approximately 300 million people worldwide. About 5–10% of all asthmatics suffer from …

Asthma is a common chronic inflammatory condition of the airways that affects about 350
million people globally. In 5%–10% of individuals, it is severe, with considerable morbidity …

Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a
decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may …

abstract Asthma is a heterogeneous disease with considerable variability noted in disease
severity, patterns of airway inflammation, and achievement of disease control on current …

Previous publications have highlighted the disparity between research trial populations and
those in clinical practice, but it has not been established how this relates to randomised …

Objective Severe asthma affects 5% to 10% of the adult asthma population and is
associated with increased morbidity, mortality, and consumption of health care resources …